Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
Ruben A. Mesa(Atrium Health Wake Forest Baptist), Srđan Verstovšek(Unknown), Donal P. McLornan(King's College London), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Aaron T. Gerds(Cleveland Clinic), Marek Hus(Medical University of Lublin), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Vikas Gupta(Indian Institute of Technology Kanpur), Uwe Platzbecker(National Center for Tumor Diseases), Barbara Klencke, Timothy Devos(Rega Institute for Medical Research), Mei Huang(Xihua University), Bryan Strouse(Sierra Engineering (United States)), Stephen T. Oh(Washington University in St. Louis), John Catalano(Frankston Hospital), Jean‐Jacques Kiladjian(Délégation Paris 5)
Cited by 63
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k